SGNTUC-019: PHASE 2 BASKET STUDY OF TUCATINIB AND TRASTUZUMAB IN SOLID TUMORS WITH HER2 ALTERATIONS: UTERINE AND CERVICAL CANCER COHORTS

1BJ Monk, 2V Kang, 3L Walker, 4D O’malley, 1Arizona Oncology (US Oncology Network), University of Arizona, Creighton University, Phoenix, AZ, USA; 5Seagen Inc., Bothell, WA, USA; 6Ohio State University, Columbus, OH, USA

10.1136/ijgc-2021-ESGO.249

Introduction/Background* Tucatinib, a highly selective HER2-directed tyrosine kinase inhibitor with minimal EGFR inhibition, is approved for use in combination with trastuzumab and capcitabine in patients with breast cancer who have received anti-HER2–based regimens in the metastatic setting. In xenograft models of HER2-overexpressed/amplified (HER2 +) and HER2-mutated tumors, dual targeting with tucatinib and trastuzumab showed superior activity to either agent alone.

The prognosis of locally-advanced unresectable or metastatic (LAUM) cervical and uterine cancer remains poor. HER2 amplification/overexpression and mutations occur in up to 21% and 80% of cervical and uterine cancers, respectively.

Methodology SGNTUC-019 (NCT04579380) is an open-label, international Phase 2 basket study evaluating tucatinib and trastuzumab in adult patients with LAUM HER2+(+) and HER2-mutated solid tumors. Multiple disease- and HER2 alteration-specific cohorts are being enrolled, including HER2+(+) cervical and uterine cancer cohorts. Patients will receive tucatinib 300 mg orally twice daily and trastuzumab 8 mg/kg IV on Cycle 1 Day 1 and 6 mg/kg q21 days from Cycle 2 Day 1.

HER2+(+) and uterine cancer cohorts will enroll 12 patients each. If ≥2 responses are observed in a cohort, it will be expanded to 30 patients. Patients with HER2-mutated cervical and uterine cancers will enroll in a cohort of 30 patients for all solid tumor types.

Eligible patients must have progressed on or after the last systemic therapy, with platinum-based therapy ± bevacizumab required in patients with metastatic cervical cancer. Patients must have ECOG PS ≤1, adequate organ function, and have not received HER2-directed therapy; patients with uterine serous carcinoma may have received trastuzumab. HER2 alterations can be demonstrated by HER2 overexpression/amplification in tumor tissue by prior IHC/ISH, or by HER2 amplification/mutation in a prior or on-study NGS assay of ctDNA or prior tissue NGS assay.

The primary endpoint is confirmed ORR per investigator. Disease control rate, duration of response, PFS, and OS are the secondary endpoints. Disease assessments per RECIST 1.1 will occur q6 weeks for 24 weeks, then q12 weeks. QoL will be evaluated q2 cycles using EQ-5D-5L.

Result(s)* Not applicable.

Conclusion* Enrollment in US began in Dec 2020; EU and Asia sites will be opened.